Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts
Top Cited Papers
Open Access
- 31 March 2009
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 100 (8) , 1315-1319
- https://doi.org/10.1038/sj.bjc.6605011
Abstract
Human epididymal secretory protein E4 (HE4, also known as WAP four-disulphide core domain protein 2) is a new promising biomarker for ovarian cancer but its specificity against ovarian endometriotic cysts is only superficially known. We, thus, analysed serum HE4 concentrations together with a tumour marker CA125 in serum samples of women diagnosed with various types of endometriosis, endometrial cancer or ovarian cancer, and in samples from healthy controls. The mean serum concentration of HE4 was significantly higher in serum samples of patients with both endometrial (99.2 pM, PP<0.001) cancer but not with ovarian endometriomas (46.0 pM) or other types of endometriosis (45.5 pM) as compared with healthy controls (40.5 pM). The serum CA125 concentrations were elevated in patients with ovarian cancer, advanced endometriosis with peritoneal or deep lesions, or ovarian endometriomas, but not in the patients with endometrial cancer. The microarray results revealed that the mRNA expression of the genes encoding HE4 and CA125 reflected the serum protein concentrations. Taken together, measuring both HE4 and CA125 serum concentrations increases the accuracy of ovarian cancer diagnosis and provides valuable information to discriminate ovarian tumours from ovarian endometriotic cysts.Keywords
This publication has 24 references indexed in Scilit:
- A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic massPublished by Elsevier ,2009
- Effects of Personal Characteristics on Serum CA125, Mesothelin, and HE4 Levels in Healthy Postmenopausal Women at High-Risk for Ovarian CancerCancer Epidemiology, Biomarkers & Prevention, 2008
- Endometrioid and clear cell ovarian cancers – A comparative analysis of risk factorsEuropean Journal Of Cancer, 2008
- Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterusGynecologic Oncology, 2008
- The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic massGynecologic Oncology, 2008
- Panel of markers can accurately predict endometriosis in a subset of patientsFertility and Sterility, 2007
- Comprehensive analysis of HE4 expression in normal and malignant human tissuesLaboratory Investigation, 2006
- Human Epididymis Protein 4 (HE4) Is a Secreted Glycoprotein that Is Overexpressed by Serous and Endometrioid Ovarian CarcinomasCancer Research, 2005
- FIGO staging classifications and clinical practice gudelines in the management of gynecologic cancersInternational Journal of Gynecology & Obstetrics, 2000
- Revised American Society for Reproductive Medicine classification of endometriosis: 1996Fertility and Sterility, 1997